What type of study is this?

Refractory ocular mucous membrane pemphigoid treated successfully with upadacitinib

View Full Paper

Ask AI

Bookmark

Significant improvement in ocular inflammation and visual acuity was observed after using upadacitinib.
Treatment escalated to 30 mg/day led to marked symptomatic relief and enhancement of visual function.
JAK1 inhibition may effectively control inflammation and fibrosis in refractory ocular mucous membrane pemphigoid.
Navigating treatment in elderly patients with comorbidities remains crucial due to potential risks of immunomodulatory therapy.

No takes yet. Share an insight, caveat, or question.

Case report shows successful treatment of ocular mucous membrane pemphigoid with upadacitinib, suggesting potential in resistant cases.

Maione et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark